Skip to main content
News
Events
Contact us
Close Search
search
Menu
About us
About us
Team
Work with us
Our offering
Our offering
FAQs
Portfolio
Success stories
Partners
Apply
Apply
FAQs
search
News
Filter
All
All
Features
Interviews
Portfolio news
Features
What startups need to know about term sheets, legal due diligence and employee incentives
Features
Building biotech companies and raising venture capital financing
Features
Raising $50M series A with Cimeio Therapeutics
Featured
Portfolio news
NXI Therapeutics Expands Management Team and Board Ahead of Next Growth Stage
Features
Basel – A Major Powerhouse in Cancer Research
Interviews
Podcast: Never underestimate the true value of IP with Philipp Marchand
Portfolio news
Anaveon presents updated data from the Phase I/II study of ANV419 during the ESMO Congress 2022
All
BaseLaunch and WuXi Biologics announce their partnership
Features
Three Pillars for Setting up Biotech Startups for Success
Portfolio news
Phialogics joins BaseLaunch Portfolio
Features
Roivant’s growth story
All
BaseLaunch and Schrödinger announce their partnership
Features
BaseLaunch’s Mission: Building Exceptional Biotech Companies
All
Charles River announces partnership with BaseLaunch
Featured
Portfolio news
InCephalo AG Announces Appointment of Lauren E. Abrey, MD as Chief Medical Officer
Features
How Lonza’s Ibex® Design 2.0 Program Accelerates Time to IND
Features
Value-based pricing in pharmaceuticals – hype or hope?
Features
Wuxi AppTec partnership with BaseLaunch renewal
All
Uncategorized
Switzerland is #1 in biotech globally according to a nature biotech study
Features
Accessing TCR Discovery Capabilities with Alloy Therapeutics
All
Uncategorized
BaseLaunch Summer Get-Toghether 2022
Features
Lonza announces collaboration with BaseLaunch
All
Features
14 legal questions every biotech startup should ask
Portfolio news
Anaveon announces starting efficacy trials with ANV419, their powerful and selective IL-2 agonist.
Portfolio news
Onena Medicines joins BaseLaunch Portfolio
Portfolio news
Engimmune Therapeutics raises $16.7M in seed financing co-led by Pureos Bioventures and Novo Holdings
Portfolio news
Cimeio Therapeutics raises a 50M USD series A financing from Versant Ventures
Features
File or fail in the age of publish or perish
Features
Your first European launch: a prescription for growth
Portfolio news
BaseLaunch – onwards and upwards
Do you have a question? Get in touch
info@baselaunch.ch
Contact us
Close Menu
About us
About us
Team
Work with us
Our offering
Our offering
FAQs
Portfolio
Success stories
Partners
Apply
Apply
FAQs
News
Events
Contact us